Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis

Jing-Ping Xiao, Ai-Ling Li, Bi-Min Feng, Yun Ye, Guo-Jun Wang

Affiliations

- PMID: 27516366
- DOI: 10.1093/pm/pnw154

Abstract

Objective: To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR.

Methods: A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI).

Results: Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID 48) scores (P < 0.00001 or P = 0.01). No statistically significant difference among all three doses of tapentadol IR and oxycodone HCL IR 10 mg on both SPID 48 and total pain relief over 48 hours (TOTPAR 48) scores (all P > 0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID 48 and TOTPAR 48 scores (all P < 0.05). For total adverse events (AEs) incidence, tapentadol IR 50 and 75 mg were significantly lower than oxycodone HCL IR 10 mg. Incidence of nausea and constipation were significantly lower with either tapentadol IR 50 or 75 mg compared with oxycodone HCL IR 10 mg (all P < 0.05).

Conclusions: Tapentadol IR 75 mg might be an optimal dose for moderate to severe pain control with fewer side effects. All three doses of tapentadol IR could provide comparable efficacy to oxycodone HCL IR 10 mg.
Keywords: Moderate to Severe Pain; Systematic Review; Tapentadol Immediate Release.

© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please email: journals.permissions@oup.com

Similar articles

• Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-day, Phase III, Randomized, Double-Blind, Active-And Placebo-Controlled Study C Hartrick et al. Clin Ther 31 (2), 260-71. Feb 2009. PMID 19302899. - Clinical Trial
  In these patients with uncontrolled osteoarthritis pain who were awaiting joint replacement surgery, tapentadol IR 50 and 75 mg were associated with analgesia that was no …

  Clinically meaningful and statistically significant improvements were observed with tapentadol IR 50 mg and 75 mg compared with placebo for the relief of moderate-to-seve …

  Multiple doses of tapentadol IR (50, 75, and 100 mg) significantly relieve acute pain after orthopedic surgery compared with placebo. These data suggest that at doses pro …

• Tapentadol Immediate Release for the Relief of Moderate-To-Severe Acute Pain CT Hartrick. Expert Opin Pharmacother 10 (16), 2687-96. Nov 2009. PMID 19795998. - Review
  Tapentadol is a novel, centrally acting analgesic with two mechanisms of action: micro-opioid receptor agonism and norepinephrine reuptake inhibition. It has demonstrated …

• Tapentadol Immediate Release: A Review of Its Use in the Treatment of Moderate to Severe Acute Pain JE Frampton. Drugs 70 (13), 1719-43. 2010. PMID 20731478. - Review
  Tapentadol (Nucynta) is an orally active, centrally acting synthetic analgesic that is thought to exert its analgesic effects via two mechanisms of action (mu-opioid rece …
  Pain therapy often entails gastrointestinal adverse events. While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies g …

  Grünenthal GmbH.

  More than 8 years after its first introduction, the favorable overall safety profile of tapentadol in the treatment of various pain conditions is maintained in the genera …